1
|
Belada D, Kopeckova K, Bergua Burgues JM, André M, Pérez Persona E, Pichler P, Klöpfer P, Brackertz B, Lohrmann E, Lahiry A, Shah N, Brugger W, Burke JM, Nowakowski GS. FIRST‐MIND: A PHASE IB, OPEN‐LABEL, RANDOMIZED STUDY TO ASSESS SAFETY OF TAFASITAMAB OR TAFASITAMAB + LENALIDOMIDE IN ADDITION TO R‐CHOP IN PATIENTS WITH NEWLY DIAGNOSED DLBCL. Hematol Oncol 2021. [DOI: 10.1002/hon.149_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- D Belada
- University Hospital and Faculty of Medicine 4th Department of Internal Medicine – Hematology Hradec Králové Czech Republic
| | - K Kopeckova
- 2nd Faculty of Medicine, Charles University and Motol University Hospital Department of Oncology Prague Czech Republic
| | | | - M André
- Université Catholique de Louvain Department of Haematology CHU UCL Namur Yvoir Belgium
| | - E Pérez Persona
- Osakidetza Basque Health Service, Araba University Hospital, Hematology Vitoria‐ Gasteiz Spain
| | - P Pichler
- University Hospital of St. Pölten Department of Internal Medicine St. Pölten Austria
| | - P Klöpfer
- MorphoSys AG Clinical Development Planegg Germany
| | - B Brackertz
- MorphoSys AG Global Patient Safety Planegg Germany
| | - E Lohrmann
- MorphoSys AG Global Patient Safety Planegg Germany
| | - A Lahiry
- MorphoSys AG Biostatistics and Data Management Planegg Germany
| | - N Shah
- MorphoSys AG Biostatistics and Data Management Planegg Germany
| | - W Brugger
- MorphoSys AG Clinical Development Planegg Germany
| | - J. M Burke
- US Oncology Research and Rocky Mountain Cancer Centers, Hematology, Aurora Colorado USA
| | | |
Collapse
|
2
|
Belada D, Kopeckova K, Bergua JM, André M, Perez Persona E, Pichler P, Klöpfer P, Brackertz B, Lohrmann E, Lahiry A, Shah N, Brugger W, Burke JM, Nowakowski GS. First-MIND: A phase Ib, open-label, randomized study to assess safety of tafasitamab (tafa) or tafa + lenalidomide (LEN) in addition to R-CHOP in patients with newly diagnosed DLBCL. J Clin Oncol 2021. [DOI: 10.1200/jco.2021.39.15_suppl.7540] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7540 Background: Tafasitamab is a humanized, Fc-modified anti-CD19 monoclonal antibody that enhances antibody-dependent cellular cytotoxicity and phagocytosis. It is FDA-approved with LEN for adult patients (pts) with relapsed/refractory (R/R) DLBCL ineligible for autologous stem cell transplantation. First-MIND (NCT04134936) is a Phase Ib, open-label, randomized study of tafa + R-CHOP or tafa + LEN + R-CHOP in newly diagnosed DLBCL. Methods: Eligible pts were ≥18 years, treatment-naïve, with histologically confirmed DLBCL not otherwise specified, international prognostic index (IPI) 2–5 and ECOG performance status (PS) 0–2. Pts with known double- or triple-hit and transformed lymphoma were excluded. Treatment (Tx) comprised six 21-day cycles of tafa (12 mg/kg IV, Day [D] 1, 8, 15) + R-CHOP (arm A) or tafa (12 mg/kg IV, D1, 8, 15) + LEN (25 mg orally, D1–10) + R-CHOP (arm B). G-CSF and VTE prophylaxis was mandatory. Primary objective is safety; secondary objectives are ORR, PET-CR rate at end of Tx, PFS, long-term safety, pharmacokinetics, immunogenicity. Results: From Dec 2019 to Aug 2020, 83 pts were screened in Europe and the US; 66 were randomized (33 per arm). Data cut-off for this analysis: 9 Dec 2020; study is ongoing. Median age was 64.5 years (range 20–86). Overall, 30% (20/66) of pts were ≥70 years and many had high-risk disease: IPI 2 29%, IPI 3 46%, IPI 4 26%. ECOG PS: 47% of pts were ECOG PS 0, 44% PS 1, 9% PS 2. Most pts had stage III/IV disease (92%); 46% had bulky disease. All pts experienced a treatment-emergent adverse event (TEAE). Grade ≥3 neutropenia and thrombocytopenia occurred in 54.5% and 12.1% (arm A) and 66.7% and 30.3% (arm B) of pts, respectively (Table). Serious TEAEs occurred in 42.4% (arm A) and 51.5% (arm B) of pts. There were three deaths, unrelated to tafa and/or LEN (sepsis, urosepsis, and COVID-19 pneumonia). R-CHOP dose intensity was maintained in both arms. Among 60 pts who completed tumor assessments after cycle 3, ORR was 89.7% (arm A) and 93.5% (arm B). Conclusions: These data suggest R-CHOP + tafa or tafa + LEN is tolerable in pts with Tx-naïve DLBCL and that R-CHOP dosing is not affected. Toxicities are similar to those expected with R-CHOP or R-CHOP + LEN. Updated safety and early efficacy data will be presented at the conference. Clinical trial information: NCT04134936. [Table: see text]
Collapse
Affiliation(s)
- David Belada
- 4th Department of Internal Medicine–Hematology, University Hospital and Faculty of Medicine, Hradec Králové, Czech Republic
| | - Katerina Kopeckova
- Department of Oncology of the 2nd Faculty of Medicine of Charles University and University Hospital in Motol, Prague, Czech Republic
| | | | - Marc André
- Department of Haematology, Université Catholique de Louvain, CHU UCL Namur, Yvoir, Belgium
| | - Ernesto Perez Persona
- Bioaraba, [Onco-Hematology Research Group],Vitoria-Gasteiz, Spain, Osakidetza Basque Health Service, Araba University Hospital,[Hematology Department], Vitoria-Gasteiz, Spain
| | - Petra Pichler
- Department of Internal Medicine, University Hospital of St. Pölten, Karl Landsteiner University of Health Sciences, Karl Landsteiner Institute for Nephrology and Hemato Oncology, St. Pölten, Austria
| | | | | | | | | | | | | | - John M. Burke
- US Oncology Research and Rocky Mountain Cancer Centers, Aurora, CO
| | | |
Collapse
|
3
|
Chamie K, Donin NM, Klöpfer P, Bevan P, Fall B, Wilhelm O, Störkel S, Said J, Gambla M, Hawkins RE, Jankilevich G, Kapoor A, Kopyltsov E, Staehler M, Taari K, Wainstein AJA, Pantuck AJ, Belldegrun AS. Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial. JAMA Oncol 2017; 3:913-920. [PMID: 27787547 DOI: 10.1001/jamaoncol.2016.4419] [Citation(s) in RCA: 89] [Impact Index Per Article: 12.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
Importance Girentuximab is a chimeric monoclonal antibody that binds carbonic anhydrase IX, a cell surface glycoprotein ubiquitously expressed in clear cell renal cell carcinoma (ccRCC). Its safety and activity in phase 2 studies prompted investigation into its use as adjuvant monotherapy in participants with high-risk ccRCC. Objective To evaluate the safety and efficacy of adjuvant girentuximab on disease-free survival (DFS) and overall survival (OS) in patients with localized completely resected high-risk ccRCC. Design, Setting, and Participants The ARISER trial (Adjuvant Rencarex Immunotherapy Phase 3 Trial to Study Efficacy in Nonmetastatic RCC) was a randomized, double-blind, placebo-controlled phase 3 clinical trial that took place between June 10, 2004, and April 2, 2013, at 142 academic medical centers in 15 countries in North and South America and Europe. Eligible adult patients had undergone partial or radical nephrectomy for histologically confirmed ccRCC and fell into 1 of the following high-risk groups: pT3/pT4Nx/N0M0 or pTanyN+M0 or pT1b/pT2Nx/N0M0 with nuclear grade 3 or greater. Patients were assigned via central computerized double-blind 1:1 randomization to receive either a single loading dose of girentuximab, 50 mg (week 1), followed by weekly intravenous infusions of girentuximab, 20 mg (weeks 2-24), or placebo, stratified by risk group and region. The data were analyzed from March 31, 2012, to April 2, 2013. Main Outcomes and Measures Co-primary end points were DFS and OS, based on imaging studies assessed by independent radiological review committee. Secondary end points included safety, assessed as the rate and grade of adverse events. Results A total of 864 patients (66% male; median [interquartile range] age, 58 [51-65] years) were randomized to girentuximab (n = 433) or placebo (n = 431). Compared with placebo, participants treated with girentuximab had no statistically significant DFS (hazard ratio, 0.97; 95% CI, 0.79-1.18) or OS advantage (hazard ratio, 0.99; 95% CI, 0.74-1.32). Median DFS was 71.4 months (interquartile range, 3 months to not reached) for girentuximab and never reached for placebo group. Median OS was never reached regardless of treatment. Drug-related adverse events occurred in 185 patients (21.6%), reported comparably between arms. Serious adverse events occurred in 72 patients (8.4%), reported comparably between arms. One drug-related serious adverse event occurred in a patient receiving placebo. Conclusions and Relevance Girentuximab had no clinical benefit as adjuvant treatment for patients with high-risk ccRCC. The surprisingly long DFS and OS in these patients represent a challenge to adjuvant ccRCC drug development. Trial Registration clinicaltrials.gov Identifier: NCT00087022.
Collapse
Affiliation(s)
- Karim Chamie
- Department of Urology, David Geffen School of Medicine at University of California, Los Angeles2Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at University of California, Los Angeles3Institute of Urologic Oncology, David Geffen School of Medicine at University of California, Los Angeles
| | - Nicholas M Donin
- Department of Urology, David Geffen School of Medicine at University of California, Los Angeles3Institute of Urologic Oncology, David Geffen School of Medicine at University of California, Los Angeles
| | - Pia Klöpfer
- Wilex AG, Munich, Germany5MorphoSys AG, Munich, Germany
| | | | - Barbara Fall
- Wilex AG, Munich, Germany6Therawis Pharma GmbH, Munich, Germany
| | - Olaf Wilhelm
- Wilex AG, Munich, Germany6Therawis Pharma GmbH, Munich, Germany
| | - Stephan Störkel
- Institute of Pathology, University of Witten/Herdeke and Helios Hospital, Wuppertal, Germany
| | - Jonathan Said
- Department of Pathology, David Geffen School of Medicine at University of California, Los Angeles
| | | | - Robert E Hawkins
- Christie Hospital NHS Trust, University of Manchester, Manchester, England
| | | | - Anil Kapoor
- Department of Clinical Oncology, McMaster University, Hamilton, Ontario, Canada
| | - Evgeny Kopyltsov
- State Institution of Healthcare Regional Clinical Oncology Dispensary, Omsk, Russia
| | - Michael Staehler
- Department of Urology, University Hospitals Munich, Campus Grosshadern, Munich, Germany
| | - Kimmo Taari
- Department of Urology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland
| | | | - Allan J Pantuck
- Department of Urology, David Geffen School of Medicine at University of California, Los Angeles2Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at University of California, Los Angeles3Institute of Urologic Oncology, David Geffen School of Medicine at University of California, Los Angeles
| | - Arie S Belldegrun
- Department of Urology, David Geffen School of Medicine at University of California, Los Angeles2Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at University of California, Los Angeles3Institute of Urologic Oncology, David Geffen School of Medicine at University of California, Los Angeles
| |
Collapse
|
5
|
Chamie K, Klöpfer P, Fall B, Said J, Störkel S, Bevan P, Belldegrun AS, Pantuck AJ. MP36-19 THE ROLE OF OBESITY IN THE INCIDENCE OF LYMPHATIC SPREAD, DISEASE-FREE AND OVERALL SURVIVAL: DATA FROM THE ARISER CLINICAL TRIAL. J Urol 2014. [DOI: 10.1016/j.juro.2014.02.1083] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|